Part B Insider - 2003 Issue 31
Pharmaceuticals: LOOKING INWARD ON MEDICAID PRICING, REBATES
Subscribe or sign in to view the full article.
Article Overview
This article covers how drug manufacturers are reexamining Medicaid pricing, rebate administration, and broader compliance practices after federal scrutiny increased. It discusses why these reviews matter, the agencies involved, and the general compliance-related steps companies may take when reconciling prior pricing activity.
Why This Topic Matters
It helps readers understand the compliance and regulatory environment around Medicaid drug pricing and rebates, and why pharmaceutical companies may need to audit internal practices in response to government attention.
What You Will Learn
- How federal scrutiny can prompt pharmaceutical compliance reviews
- Why Medicaid pricing and rebate practices are under review
- Which government agencies may be involved in pricing and rebate matters
- How manufacturers may respond to identified compliance issues
Who Should Read This
- Pharmaceutical compliance professionals
- Drug manufacturer finance and accounting teams
- Healthcare regulatory analysts
- Medical billing and reimbursement professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com